Compare Pfizer Inc (PFE) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Taskus Inc — how do they compare? Pfizer Inc trades at $27.75 (market cap $159.59B), while Taskus Inc trades at $7.99 (market cap $723.41M). The key difference: Pfizer Inc is far larger — about 220.6× Taskus Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Taskus Inc for 34 Days on average.
| PFE | TASK | |
|---|---|---|
Market Cap | $159.59B | $723.41M |
Volume | 30,937,010 | 201,303 |
Sector | Health | Technology |
52-Week High | $29.02 | $14.69 |
52-Week Low | $23.67 | $4.57 |
Typical Hold Time | 158 Days | 34 Days |
Enterprise Value | $211.09B | $1.09B |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
TaskUs trades at $8.01, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expansion to 8.75%. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected, driven by AI services growth offsetting Trust & Safety declines.
The stock appears undervalued with P/E of 6.8 and P/S of 0.6, supported by analyst consensus target of $9.33 representing 16% upside. Key risks include labor cost pressures and client concentration, while AI segment growth at 26% provides upside catalyst. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
